93606 Federal Register / Vol. 89, No. 229 / Wednesday, November 27, 2024 / Notices 

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)—Continued 

[Study eligibility criteria based on Population, Intervention, Comparator, Outcome (PICO), and other elements] 

Element Inclusion criteria Exclusion criteria 

Key Question 2: 

• Minimum follow-up 

Æ If population has no CV risk factors (or 

unselected general population): 10 years 

Æ If population has one or more CV risk factors: 5 

years 

Setting .................................. • General community settings, including nursing 

homes, assisted living facilities, etc. 

• Hospital or other acute care settings. 

• Institutionalized, confined settings (e.g., prisons). 

Publication ............................ • English language 

• Published in peer-reviewed journals 

* Minimum sample size may be altered depending on the number of eligible studies found. 

† Applying this approach for the 2016 AHRQ report n-3 fatty acids and cardiovascular disease (https://doi.org/10.23970/AHRQEPCERTA223), 

we included: for cardiac event outcomes, observational studies with at least 10,000 participants; for stroke outcomes, at least 3000 participants; 

for arrhythmia outcomes, at least 2000 participants; congestive heart failure outcomes, at least 700 participants; and for peripheral vascular disease events and MACE outcomes, at least 500 participants. In all instances, if a study meets eligibility criteria for any outcome, we will extract all 

outcomes of interest from that study; therefore, there will be multiple instances of studies being included for an outcome even though the study 

might not have met study size criteria for that specific outcome. 

CV = cardiovascular; CVD = cardiovascular disease; PUFA = polyunsaturated fatty acids; ALA = alpha-linolenic acid; EPA = eicosapentaenoic 

aci; DHA= docosahexaenoic acid; DPA = docosapentaenoic acid; n-3 = Omega 3; n-6 = Omega 6; FA = fatty acid; c = cholesterol; LDL = lowdensity lipoprotein; IDL = intermediate-density lipoprotein; HDL high-density lipoprotein; TC—total cholesterol; Tg = Triglycerides/Triacylglycerols; 

apoA = apolipoprotein; MAC[C]E = Major adverse cardiac (or cerebro) events; BMI = body mass index; KQ = key question; N = number of 

participants. 

Dated: November 21, 2024. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2024–27798 Filed 11–26–24; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

CE25–021, Research Grants for 

Preventing Violence and Violence 

Related Injury. 

Dates: February 19–20, 2025. 

Times: 10 a.m.–5 p.m., EST. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Carlisha Gentles, Pharm.D., B.C.P.S., 

C.D.C.E.S., Scientific Review Officer, 

National Center for Injury Prevention 

and Control, Centers for Disease Control 

and Prevention, 4770 Buford Highway 

NE, Mailstop S106–9, Atlanta, Georgia 

30341. Telephone: (770) 488–1504; 

Email: CGentles@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–27857 Filed 11–26–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, pursuant to Public Law 92– 

463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel; 

(SEP)—CE25–025, Rigorous Evaluation 

of Community- and Societal-Level 

Primary Prevention Approaches to 

Prevent Adverse Childhood Experiences 

(ACEs): Expanding the Best Available 

Evidence. 

Dates: February 25–26, 2025. 

Times: 10 a.m.–5 p.m., EST. 

Place: Web Conference. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 229 / Wednesday, November 27, 2024 / Notices 93607 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341. 

Telephone: (404) 639–6473; Email: 

AWilkes@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–27856 Filed 11–26–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10891] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by December 27, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: New collection (Request for a 

new OMB control number); Title of 

Information Collection: Medicaid 

Program; Medicare Savings Program 

Application and Eligibility 

Determinations; Use: The provisions in 

this collection of information request 

are necessary for helping to enroll 

individuals into the Medicare Savings 

Programs (MSPs) as directed by the 

Medicare Improvements for Patients and 

Providers Act of 2008 (MIPPA) and for 

implementing the September 21, 2023 

(88 FR 65230) final rule entitled, 

‘‘Streamlining Medicaid: Medicare 

Savings Program Eligibility 

Determination and Enrollment’’ 

(hereinafter ‘‘MSP final rule’’) (CMS– 

2421–F; RIN 0938–AU00). 

CMS did not previously estimate 

several costs for implementing the 

provisions of MIPPA related to MSPs as 

well as costs related to MSPs that were 

longstanding costs inherent to the 

Medicaid program that predated MIPPA. 

To address that oversight, we estimate 

such burden in this collection of 

information request. We also estimate 

burden and savings associated with the 

provisions in the MSP final rule. Such 

burden was set out in the Regulatory 

Impact Analysis section of the final rule. 

The MSPs are essential to the health 

and well-being of those enrolled, 

promoting access to care and helping 

free up individuals’ limited income for 

food, housing, and other life necessities. 

Through the MSPs, Medicaid pays 

Medicare Part B premiums each month 

for over 10 million individuals and Part 

A premiums for over 700,000 

individuals. State Medicaid agencies 

receive applications and adjudicate 

eligibility for MSP coverage. 

MIPPA created new requirements for 

states to leverage the Medicare Part D 

Low-Income Subsidy (LIS) program to 

help enroll likely-eligible individuals in 

MSPs, and the MSP final rule expanded 

those requirements. States use 

information collected by the Social 

Security Administration on the LIS 

application (transmitted to states with 

the consent of an individual completing 

an application) to determine eligibility 

for the MSPs. Under the MSP final rule, 

the state Medicaid agency accepts and 

verifies the information provided on the 

LIS application (to the extent allowable 

under the MSP final rule); 

communicates with the applicant or the 

authorized representative about any 

additional information needed to make 

an MSP determination; makes the MSP 

eligibility determination; enrolls the 

individual in an MSP, if eligible; and 

informs the individual about the rights 

and responsibilities for applying for full 

Medicaid eligibility. Applicants include 

anyone who chooses to apply for LIS 

and provides consent for their 

application to be considered for MSPs. 

In addition to building on MIPPA and 

strengthening the LIS pathway for 

enrolling in MSPs, the MSP final rule 

streamlined MSP eligibility and 

enrollment processes, reduced 

administrative burden on states and 

applicants, and increased enrollment 

and retention of eligible individuals. 


ddrumheller on DSK120RN23PROD with NOTICES1